FindTrial
Sign In

Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN19844007
Enrollment
80
Registered
2006-09-29
Start date
2005-07-27
Completion date
Unknown
Last updated
2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia Haematological Disorders Other anaemias

Interventions

Not provided at time of registration

Sponsors

Record Provided by the NHSTCT Register - 2006 Update - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Control of haemoglobin and use of erythropoietin—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026